Rossari BiotechQ2 FY24

Rossari Biotech Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹432.9P/E: 15.7Market Cap: ₹2.4K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2
  • Rossari Biotech anticipates strong future growth driven by capacity expansions at Dahej and Unitop, including a 20,000 MTPA capacity increase at Dahej and an additional 30,000 MTPA Ethoxylation capacity at Unitop to meet rising demand.
  • The new CAPEX of Rs. 178 crore planned in phases over 12-18 months is expected to enable incremental sales of about Rs. 600-700 crore at peak capacity within 2-4 years.
  • Current capacity utilization is high (near 100% at Unitop and Tristar, 78-80% at Dahej), indicating strong demand with some lost orders due to capacity constraints.
  • Growth is expected across segments, notably HPPC (Agro, Phenoxy, Institutional Cleaning, Paints, Home & Personal Care), and export markets for Agro surfactants.
  • Textile Chemicals business outlook is positive from January 2024 with focus on Bangladesh and select international markets.
  • Management projects continued volume-driven growth, prioritizing capacity utilization over margins in the near term.

See what Rossari Biotech management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • The company plans to fund its ongoing and future CAPEX (capacity expansion) through a balanced mix of internal accruals and external debt.
  • No specific debt quantum has been finalized yet, but management is comfortable with current debt-to-equity ratios and repayment capacity.
  • For FY24, some debt may be raised depending on cash levels and CAPEX requirements, with CAPEX spread over 12 to 18 months.
  • No mention of any new equity fundraising during the call.
  • Management expressed confidence in their strong balance sheet and ability to manage debt comfortably even if the entire CAPEX is debt-funded.

See what Rossari Biotech management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Rs. 50 crore allocated for Dahej facility expansion (completion expected by Q3 FY25).
  • Rs. 128 crore assigned to Ethoxylation capacity expansion at Unitop, increasing capacity by 30,000 MTPA (phased execution over next 12-18 months).
  • Total announced CAPEX around Rs. 178 crore, with about Rs. 125-130 crore expected to be spent in the current year.
  • CAPEX financed through a mix of internal accruals and external debt, with manageable debt levels.
  • Investments aim to support growth in HPPC division and related products for the Home & Personal Care (HPPC) segment.
  • Additional tank farms and debottlenecking done to support Ethoxylation capacity and production needs.
  • Future scope for further expansion exists due to available land, especially at Unitop site.
  • Expected incremental annual sales potential of Rs. 600 crore over 2-4 years upon peak capacity utilization.

Track Rossari Biotech — get its next earnings analysis in your feed

How does Rossari Biotech rank vs peers in Chemicals & Petrochemicals?

Pro feature
ThisRossari Biotech
Rev 2Mar 3

How does Rossari Biotech rank in Chemicals & Petrochemicals?

Compare Rossari Biotech against every Chemicals & Petrochemicals company (Q2 FY24) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

Others in Chemicals & Petrochemicals this season

  • Seya Industries (Q2 FY27)

    Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's

  • DCM Shriram Fine Chemicals (Q2 FY27)

    9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri

  • Dhariwalcorp (Q2 FY27)

    For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…

  • Agastya Energy (Q2 FY27)

    For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →